These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 30981205)

  • 1. MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway.
    Huang G; Lou T; Pan J; Ye Z; Yin Z; Li L; Cheng W; Cao Z
    Aging (Albany NY); 2019 Apr; 11(7):2138-2150. PubMed ID: 30981205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
    Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
    Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
    Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
    Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-29c reduces the cisplatin resistance of non-small cell lung cancer cells by negatively regulating the PI3K/Akt pathway.
    Sun DM; Tang BF; Li ZX; Guo HB; Cheng JL; Song PP; Zhao X
    Sci Rep; 2018 May; 8(1):8007. PubMed ID: 29789623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling.
    Huang RS; Zheng YL; Zhao J; Chun X
    Biomed Pharmacother; 2018 Feb; 98():538-544. PubMed ID: 29287202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of TRIM65 inhibits autophagy and cisplatin resistance in A549/DDP cells by regulating miR-138-5p/ATG7.
    Pan X; Chen Y; Shen Y; Tantai J
    Cell Death Dis; 2019 Jun; 10(6):429. PubMed ID: 31160576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deregulation of lncRNA-AC078883.3 and microRNA-19a is involved in the development of chemoresistance to cisplatin via modulating signaling pathway of PTEN/AKT.
    Xing S; Qu Y; Li C; Huang A; Tong S; Wu C; Fan K
    J Cell Physiol; 2019 Dec; 234(12):22657-22665. PubMed ID: 31111480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
    Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
    Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis.
    Fu J; Cai H; Wu Y; Fang S; Wang D
    Gene; 2020 Sep; 755():144886. PubMed ID: 32534055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.
    Ni L; Xu J; Zhao F; Dai X; Tao J; Pan J; Shi A; Shen Z; Su C; Zhang Y
    Eur J Pharmacol; 2021 May; 899():174054. PubMed ID: 33771522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer.
    Xu L; Huang Y; Chen D; He J; Zhu W; Zhang Y; Liu X
    Cancer Genet; 2014 May; 207(5):214-20. PubMed ID: 24906642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-25-3p promotes cisplatin resistance in Non-small-cell lung carcinoma (NSCLC) through adjusting PTEN/PI3K/AKT route.
    Sun B; Hu N; Cong D; Chen K; Li J
    Bioengineered; 2021 Dec; 12(1):3219-3228. PubMed ID: 34266345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of miR-15b partially reverses the cisplatin resistance of NSCLC through the GSK-3β/MCL-1 pathway.
    Lu T; Lu W; Jia C; Lou S; Zhang Y
    Adv Clin Exp Med; 2021 Aug; 30(8):849-857. PubMed ID: 34286518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sulforaphane inhibits cancer stem-like cell properties and cisplatin resistance through miR-214-mediated downregulation of c-MYC in non-small cell lung cancer.
    Li QQ; Xie YK; Wu Y; Li LL; Liu Y; Miao XB; Liu QZ; Yao KT; Xiao GH
    Oncotarget; 2017 Feb; 8(7):12067-12080. PubMed ID: 28076844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
    Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
    Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exosomal Transfer Of Cisplatin-Induced miR-425-3p Confers Cisplatin Resistance In NSCLC Through Activating Autophagy.
    Ma Y; Yuwen D; Chen J; Zheng B; Gao J; Fan M; Xue W; Wang Y; Li W; Shu Y; Xu Q; Shen Y
    Int J Nanomedicine; 2019; 14():8121-8132. PubMed ID: 31632022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
    Qi MM; Ge F; Chen XJ; Tang C; Ma J
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2.
    Qiu T; Zhou L; Wang T; Xu J; Wang J; Chen W; Zhou X; Huang Z; Zhu W; Shu Y; Liu P
    Int J Mol Med; 2013 Sep; 32(3):593-8. PubMed ID: 23856992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer.
    Yu S; Qin X; Chen T; Zhou L; Xu X; Feng J
    Anticancer Drugs; 2017 Sep; 28(8):852-860. PubMed ID: 28723865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis.
    Huang Q; Xing S; Peng A; Yu Z
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.